Option chain shows key data for Nexalin Technology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nexalin Technology.

Nexalin Technology (NASDAQ:NXLIW) Stock, Option Chain

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Biotech

News

Health Care

Exclusives

General

NXLIW

Nexalin says the study published in the Journal of Alzheimer&#39;s Disease shows DIFS may enhance cognition in mild Alzheimer&#39;s patients.

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer&#39;s Patients (UPDATED)

Market-Moving Exclusives

Nexalin Technology&#39;s clinical trial results highlight notable cognitive improvements in Alzheimer&#39;s patients using Deep Intracranial Frequency Stimulation technology. The study showed significant memory and cognition gains, increased hippocampal activity, and minimal side effects.

EXCLUSIVE: Nano-Cap Nexalin&#39;s Drug-Free Alternative For Alzheimer&#39;s Shows Improved Memory, Cognitive Function In Small Study

Nexalin Technology Inc

Press Releases

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity  in Clinical Trials for mTBI and PTSD Treatment

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Nexalin Technology

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Nexalin Technology

Nexalin Technology (NXLIW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga